BD Reports Second Quarter Fiscal 2024 Financial Results : vimarsana.com

Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024
Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organicQ2 GAAP and...

Related Keywords

United States , China , Singapore , Russia , Ukraine , America , Tom Polen , Troy Kirkpatrick , Exchange Commission , Bd Life Sciences , Medication Delivery Solutions , Camtech Health , Business Group On Health , Linkedin , Medication Management Solutions , Diagnostics Solutions , America Most Innovative Companies , Clinical Solutions , European Union Medical Device Regulation , Margin Execution Drives Better Performance , Higher Guidance , Continuing Operations , Free Cash Flow , Corporate Sustainability , Automated Dispensing Cabinet , Integrated Diagnostics Solutions , Peripheral Intervention , Covered Stent , Peripheral Arterial , Most Innovative Companies , Best Employer , Employee Well Being , Business Group , Quarter Fiscal , Diluted Earnings , Months Ended March , Pharmaceutical Systems , Vascular Access Management , Infusion System , Pharmacy Automation , Integrated Diagnostic Solutions , Blood Culture , Clinical Reagents , Clinical Cell Analyzer , Sample Preparation System , Critical Care , Infection Prevention , Surgical Instrumentation , Peripheral Vascular Disease , Atherectomy System , Full Year Fiscal , Revenue Growth , Surgical Instrumentation Platform , Foreign Currency Impact , Adjusted Diluted , Devices Regulations , Middle East , Adam Reiffe , Investor Relations , Public Relations , Cash Provided , Continuing Operating , Diabetes Care , Foreign Currency , Share Percentage , Markets ,